Philippe Legenne
GlaxoSmithKline
18 Papers
60 Citations
Philippe Legenne is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 10 publications.
Chat about Author
Papers
Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).
Kevin J. Harrington,A. Berrier,Martin Robinson,Éva Remenár,M. Housset,F. Hurtado de Mendoza,Natalie Compton,M. Lau,Philippe Legenne,Ritesh Kumar +9 more
TL;DR: Lapatinib is an oral, reversible small-molecule inhibitor of epidermal growth factor receptor (EGFR) and human Epidermal Growth Factor receptor-2 (HER2) and EGFR overexpression is reported to be a novel mechanism of action for EGFR inhibition.
27
Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).
Kevin J. Harrington,Stéphane Temam,Anil K. D'Cruz,Minish Mahendra Jain,Ida D'Onofrio,Georgy M. Manikhas,Geza Horvai,Yan Sun,Stefan Dietzsch,Pavol Dubinsky,Petra Holečková,Hisham Mehanna,Iman El-Hariry,Natalie Franklin,Nigel Biswas-Baldwin,Philippe Legenne,Paul Wissel,Thelma Netherway,Sergio Santillana,Jean Bourhis +19 more
TL;DR: This study enrolled patients with resected stage II-IVA SCCHN, with a surgical margin ≤5mm and/or extracapsular extension, and found that L, a tyrosine kinase inhibitor of both EGFR and ErbB2, demonstrates tumor responses in SCCHn.
24
Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors.
Bojana Milojkovic Kerklaan,Martijn P. Lolkema,Lot A. Devriese,Emile E. Voest,A. Nol-Boekel,Marja Mergui-Roelvink,K. Mykulowycz,Joseph E Stoebenau,Lei Fang,Philippe Legenne,Paul Wissel,Deborah A. Smith,Bruce J. Giantonio,Jan H.M. Schellens,Petronella O. Witteveen +14 more
TL;DR: This interim report describes the bioavailability and safety results for daily pazopanib combined with oral topotecan in a 28-day cycle and describes the death due to hepatic failure and the most frequent treatment-related toxicities.
9
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer
Peter G. Rose,Bradley J. Monk,Diane Provencher,Jean Hartney,Philippe Legenne,Stephen J. Lane +5 more
TL;DR: This study showed an acceptable benefit-risk profile for topotecan plus carboplatin in patients with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal carcinoma and further studies using alternative dose levels could help define an optimal dosing schedule.
7
Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study
Nina Stojcheva,Stacy Gladman,Marianne Soergel,Christof Zitt,Roxana F Drake,Tony Lockett,Pierre Fustier,Vaia Stavropoulou,Adeep Puri,Randall Watson,Philippe Legenne,Michael T. Stumpp,Malcolm Boyce +12 more
TL;DR: In this article , ensovibep, a designed ankyrin repeat protein antivirus, was evaluated as a COVID-19 treatment in healthy volunteers in a first-in-human ascending single-dose study.
3